Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = TOPK inhibitor OTS964

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 2731 KiB  
Article
PD-L1-Targeted Co-Delivery of Two Chemotherapeutics for Efficient Suppression of Skin Cancer Growth
by Fatemeh Movahedi, Jie Liu, Bing Sun, Pei Cao, Luyao Sun, Christopher Howard, Wenyi Gu and Zhi Ping Xu
Pharmaceutics 2022, 14(7), 1488; https://doi.org/10.3390/pharmaceutics14071488 - 18 Jul 2022
Cited by 1 | Viewed by 2286
Abstract
To overcome the severe side effects of cancer chemotherapy, it is vital to develop targeting chemotherapeutic delivery systems with the potent inhibition of tumour growth, angiogenesis, invasion and migration at low drug dosages. For this purpose, we co-loaded a conventional antiworm drug, albendazole [...] Read more.
To overcome the severe side effects of cancer chemotherapy, it is vital to develop targeting chemotherapeutic delivery systems with the potent inhibition of tumour growth, angiogenesis, invasion and migration at low drug dosages. For this purpose, we co-loaded a conventional antiworm drug, albendazole (ABZ), and a TOPK inhibitor, OTS964, into lipid-coated calcium phosphate (LCP) nanoparticles for skin cancer treatment. OTS- and ABZ-loaded LCP (OTS-ABZ-LCP) showed a synergistic cytotoxicity against skin cancer cells through their specific cancerous pathways, without obvious toxicity to healthy cell lines. Moreover, dual-targeting the programmed death ligand-1 (PD-L1) and folate receptor overexpressed on the surface of skin cancer cells completely suppressed the skin tumour growth at low doses of ABZ and OTS. In summary, ABZ and OTS co-loaded dual-targeting LCP NPs represent a promising platform with high potentials against complicated cancers where PD-L1/FA dual targeting appears as an effective approach for efficient and selective cancer therapy. Full article
(This article belongs to the Special Issue Advances in Stimuli-Responsive Tumor Targeting Nanotechnology)
Show Figures

Graphical abstract

Back to TopTop